Neuroendocrine Tumor Treatment Market Size, Share & Trends Analysis Report By Site (Small Intestine, Pancreas), By End Use (Hospitals, Clinics), By Product (SSA, Targeted Therapy), And Segment Forecasts, 2018 - 2025

Published: Nov, 2018 | Pages: 100 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global neuroendocrine tumor (NET) treatment market size is expected to reach USD 3.33 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to register a CGAR of 10.4% during the forecast period. Increasing pervasiveness of carcinoid tumors is expected to drive the market over the forecast period. Heavy investment in clinical trials by various pharmaceutical companies to develop novel products is another factor propelling the market development.

For instance, Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma. Moreover, technological advancements in therapies to treat neuroendocrine tumors are anticipated to fuel the market growth over the coming years. Some of these include PET imaging with Ga labeled Somatostatin, targeted drug therapies, and tyrosine kinase therapies. For instance, Lutathera by Novartis AG received FDA approval for the first ever radionucleotide therapy.

Further key findings from the study suggest:

• Somatostatin analogs segment accounted for the largest revenue share of more than 60% in 2017 owing to its cost-effective and safe therapy procedure

• The pancreas segment is expected to exhibit the highest growth in the neuroendocrine tumor treatment market over the forecast period

• Clinics segment is expected to register the highest CAGR of 10.9% over the estimated period due to increasing patient preference for clinics over other healthcare settings

• North America held the largest share of the global neuroendocrine tumor treatment market in 2017 mainly due to favorable government insurance policies

• Some of the key companies in the global market are Pfizer, Inc.; Novartis AG; Ipsen Pharma; and Boehringer Ingelheim International GmbH. Major companies focus more on R&D to develop novel therapeutics for NETs.

 Table of Contents

Chapter 1 Report Scope
                 1.1 Segment Market Scope
                 1.2 Regional Scope
                 1.3 Estimates & Forecast Timeline

Chapter 2 Research Methodology
                 2.1 Model Details
                     2.1.1 Regression and variable analysis
                 2.2 Information Procurement
                 2.3 List Of Primary Sources
                     2.3.1 Purchased database:
                     2.3.2 GVR's internal database
                 2.4 Primary Interview Breakup
                     2.4.1 Data for primary interviews, by sources
                     2.4.2 Data for primary interviews, by region
                 2.5 List Of Secondary Sources

Chapter 3 Report Objectives
                 3.1 Objectives

Chapter 4 Executive Summary
                 4.1 Market Summary

Chapter 5 Market Definitions
                 5.1 Definitions

Chapter 6 Neuroendocrine tumor treatment market: Industry Outlook
                 6.1 Market Variable Analysis
                 6.2 Market Driver Analysis
                     6.2.1 Increasing prevalence of neuroendocrine carcinoma
                     6.2.2 Technological advancements
                     6.2.3 Ongoing clinical
                     6.2.4 Rising number of government initiatives
                 6.3 Market Restraints Analysis
                     6.3.1 High cost of development
                     6.3.2 Lack of awareness among people
                 6.4 Business Environment Analysis Tools
                     6.4.1 Neuroendocrine tumor treatment market - SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
                     6.4.2 Porter's Five Forces Analysis

Chapter 7 Regulatory & Political Forces
                 7.1 Regulatory Landscape
                     7.1.1 List of regulations, by country
                     7.1.2 U.S.
                     7.1.3 Canada
                     7.1.4 Europe
                     7.1.5 China
                     7.1.6 India
                     7.1.7 Mexico
                     7.1.8 Brazil
                     7.1.9 South Africa
                 7.2 Political Landscape, Current & Future Scenario

Chapter 8 Competitive & Vendor Landscape
                 8.1 Market Participation Categorization
                     8.1.1 Market leader
                     8.1.2 Innovators
                 8.2 Strategic Initiatives & Outcome Analysis
                 8.3 List of Key Companies, By Product
                 8.4 Company Market Share Analysis
                     8.4.1 Neuroendocrine tumor treatment market company market share analysis, 2017

Chapter 9 Neuroendocrine Tumor Treatment Market: Product Analysis
                 9.1 Product Business Analysis
                 9.2 Somatostatin Analogs (SSA)
                     9.2.1 Somatostatin analogs (SSA) estimates and forecasts, 2014 - 2025 (USD Million)
                 9.3 Targeted Therapy
                     9.3.1 Targeted therapy market estimates and forecasts, 2014 - 2025 (USD Million)
                 9.4 Others
                     9.4.1 others market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 10 Neuroendocrine Tumor Treatment Market: Site Analysis
                 10.1 Site Business Analysis
                 10.2 Lungs
                     10.2.1 Lungs estimates and forecasts, 2014 - 2025 (USD Million)
                 10.3 Pancreas
                     10.3.1 pancreas market estimates and forecasts, 2014 - 2025 (USD Million)
                 10.4 Colon
                     10.4.1 colon market estimates and forecasts, 2014 - 2025 (USD Million)
                 10.5 Small Intestine
                     10.5.1 small intestine market estimates and forecasts, 2014 - 2025 (USD Million)
                 10.6 Others
                     10.6.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 11 Neuroendocrine tumor treatment market: End-use Analysis
                 11.1 End-use Business Analysis
                 11.2 Hospitals
                     11.2.1 hospitals estimates and forecasts, 2014 - 2025 (USD Million)
                 11.3 Clinics
                     11.3.1 clinics market estimates and forecasts, 2014 - 2025 (USD Million)
                 11.4 Others
                     11.4.1 others market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 12 Neuroendocrine tumor treatment market: Regional Analysis
                 12.1 North America
                     12.1.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.1.2 U.S.
                          12.1.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.1.3 Canada
                          12.1.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                 12.2 Europe
                     12.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.2 Germany
                          12.2.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.3 U.K.
                          12.2.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                 12.3 Asia Pacific
                     12.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.2 China
                          12.3.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.3 India
                          12.3.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.4 Japan
                          12.3.4.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                 12.4 Latin America
                     12.4.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.4.2 Mexico
                          12.4.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.4.3 Brazil
                          12.4.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                 12.5 MEA
                     12.5.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.5.2 South Africa
                          12.5.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 13 Company Profiles
                 13.1 Key Company Profiles
                     13.1.1 Novartis AG
                          13.1.1.1 Company overview
                          13.1.1.2 Financial performance
                          13.1.1.3 Product benchmarking
                          13.1.1.4 Strategic initiatives
                     13.1.2 Boehringer Ingelheim International GmbH
                          13.1.2.1 Company overview
                          13.1.2.2 Financial performance
                          13.1.2.3 Product benchmarking
                          13.1.2.4 Strategic initiatives
                     13.1.3 Dauntless Pharmaceuticals
                          13.1.3.1 Company overview
                          13.1.3.2 Product benchmarking
                          13.1.3.3 Strategic initiatives
                     13.1.4 Hutchison MediPharma Limited
                          13.1.4.1 Company overview
                          13.1.4.2 Product benchmarking
                          13.1.4.3 Strategic initiatives
                     13.1.5 AVEO Oncology
                          13.1.5.1 Company overview
                          13.1.5.2 Financial Performance
                          13.1.5.3 Product benchmarking
                          13.1.5.4 Strategic initiatives
                     13.1.6 Pfizer Inc.
                          13.1.6.1 Company overview
                          13.1.6.2 Financial performance
                          13.1.6.3 Product benchmarking
                          13.1.6.4 Strategic initiatives
                     13.1.7 Ipsen Pharma
                          13.1.7.1 Company overview
                          13.1.7.2 Product benchmarking
                          13.1.7.3 Strategic initiatives
                     13.1.8 Progenics Pharmaceuticals, Inc.
                          13.1.8.1 Company overview
                          13.1.8.2 Financial performance
                          13.1.8.3 Product benchmarking
                          13.1.8.4 Strategic initiatives
                     13.1.9 Tarveda Therapeutics
                          13.1.9.1 Company overview
                          13.1.9.2 Product benchmarking
                          13.1.9.3 Strategic initiatives
                     13.1.10 Exelixis, Inc.
                          13.1.10.1 Company overview
                          13.1.10.2 Financial performance
                          13.1.10.3 Product benchmarking
                          13.1.10.4 Strategic initiatives

Chapter 14 Recommendations/Conclusion
                 14.1 Recommendations
                 14.2 Conclusion

List of Tables

Table 1 Country share estimation
Table 2 List of regulations, by country
Table 3 List of key companies, by product
Table 4 North America neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 5 North America neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 6 North America neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 7 U.S. neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 8 U.S. neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 9 U.S. neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 10 Canada neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 11 Canada neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 12 Canada neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 13 Europe neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 14 Europe neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 15 Europe neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 16 Germany neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 17 Germany neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 18 Germany neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 19 U.K. neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 20 U.K. neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 21 U.K. neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 22 Asia Pacific neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 23 Asia Pacific neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 24 Asia Pacific neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 25 China neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 26 China neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 27 China neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 28 India neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 29 India neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 30 India neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 31 Latin America neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 32 Latin America neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 33 Latin America neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 34 Mexico neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 35 Mexico neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 36 Mexico neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 37 Brazil neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 38 Brazil neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 39 Brazil neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 40 MEA neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 41 MEA neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 42 MEA neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)
Table 43 South Africa neuroendocrine tumor treatment market, by product, 2014 - 2025 (USD Million)
Table 44 South Africa neuroendocrine tumor treatment market, by site, 2014 - 2025 (USD Million)
Table 45 South Africa neuroendocrine tumor treatment market, by end - use, 2014 - 2025 (USD Million)

List of Figures

Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Value chain - based sizing & forecasting
Fig. 4 QFD modeling for market share assessment
Fig. 5 Components: TAM
Fig. 6 Information procurement
Fig. 7 Primary interviews, by sources
Fig. 8 Primary interviews, by region
Fig. 9 Neuroendocrine tumor treatment market revenues, 2017, (USD Millions)
Fig. 10 Market trends & outlook
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Neuroendocrine tumor treatment market - SWOT analysis, by the factor (political & legal, economic and technological)
Fig. 14 Porter's five forces analysis
Fig. 15 Market participant categorization
Fig. 16 Strategy framework analysis, 2017
Fig. 17 Neuroendocrine tumor treatment market share, 2017
Fig. 18 Neuroendocrine tumor treatment market product outlook: Key takeaways
Fig. 19 Neuroendocrine tumor treatment market: Product movement analysis
Fig. 20 Global somatostatin analog market, 2014 - 2025 (USD Million)
Fig. 21 Global targeted therapy market, 2014 - 2025 (USD Million)
Fig. 22 Global others market, 2014 - 2025 (USD Million)
Fig. 23 Neuroendocrine tumor treatment market site outlook: Key takeaways
Fig. 24 Neuroendocrine tumor treatment market: Site movement analysis
Fig. 25 Global lungs market, 2014 - 2025 (USD Million)
Fig. 26 Global pancreas market, 2014 - 2025 (USD Million)
Fig. 27 Global colon market, 2014 - 2025 (USD Million)
Fig. 28 Global small intestine market, 2014 - 2025 (USD Million)
Fig. 29 Global others market, 2014 - 2025 (USD Million)
Fig. 30 Neuroendocrine tumor treatment market end use outlook: Key takeaways
Fig. 31 Neuroendocrine tumor treatment market: End - use movement analysis
Fig. 32 Global hospitals market, 2014 - 2025 (USD Million)
Fig. 33 Global clinics market, 2014 - 2025 (USD Million)
Fig. 34 Global others market, 2014 - 2025 (USD Million)
Fig. 35 Regional marketplace: Key takeaways
Fig. 36 Regional outlook, 2014 - 2025 (USD Million)
Fig. 37 North America Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 38 U.S. Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 39 Canada Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 40 Europe Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 41 Germany Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 42 U.K. Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 43 Asia Pacific Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 44 China Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 45 India Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 46 Latin America Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 47 Mexico Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 48 Brazil Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 49 MEA Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)
Fig. 50 South Africa Neuroendocrine tumor treatment market, 2014 - 2025 (USD Million)